title: An accelerated pathway for targeted cancer therapies.
abstract: A well-defined pathway for the accelerated development and approval of targeted cancer therapies and companion diagnostics would reduce uncertainty, improve efficiency in development and provide an effective incentive for developers.
authors.affiliation: Engelberg Center for Health Care Reform, Brookings Institution, Washington DC, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: McClellan
authors.forename: Joshua
authors.initials: J
authors.lastname: Benner
authors.forename: Richard
authors.initials: R
authors.lastname: Schilsky
authors.forename: David
authors.initials: D
authors.lastname: Epstein
authors.forename: Ray
authors.initials: R
authors.lastname: Woosley
authors.forename: Stephen
authors.initials: S
authors.lastname: Friend
authors.forename: David
authors.initials: D
authors.lastname: Sidransky
authors.forename: Cindy
authors.initials: C
authors.lastname: Geoghegan
authors.forename: David
authors.initials: D
authors.lastname: Kessler
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry; D002986:Clinical Trials as Topic / Q000639:trends; D016503:Drug Delivery Systems / Q000639:trends*; D055808:Drug Discovery / Q000639:trends*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents